Published 7/14/2026
Vasu S, Denlinger N, Song NJ, Elsberry D, Zhao Q, Yu L, Bezerra ED, Szuminski N, Schneider D, Dash P, Wirthlin L, Epperla N, Sawalha Y, Woyach JA, Nishat S, Rogers KA, Bhat SA, Ghoneim HE, Behbehani GK, Voorhees TJ, Larkin K, Kittai AS, Churchill V, George E, Lamb M, Lee DA, Chan WK, Krull A, Orentas RJ, O'Donnell L, Li Z, Alinari L, de Lima M. Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22. Blood Cancer Discov. 2026 Jul 14. PMID: 42446920.
Published 2/9/2026
Vasu S, Denlinger N, Song NJ, Elsberry D, Zhao Q, Yu L, Bezerra E, Szuminski N, Schneider D, Dash P, Wirthlin L, Epperla N, Sawalha Y, Woyach J, Nishat S, Rogers K, Bhat S, Ghoneim H, Behbehani G, Voorhees T, Larkin K, Kittai A, Churchill V, George E, Lamb M, Lee D, Chan W, Krull A, Orentas R, O'Donnell L, Li Z, Alinari L, de Lima M. Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22. Res Sq. 2026 Feb 09. PMID: 41727591.